Key Takeaways
- New Therapies: Risvodetinib and high-dose Vitamin B3 (NR) have shown positive safety and efficacy results in early clinical trials.
- Genetic Diversity: The BLAAC PD study is expanding to four new US sites to better understand Parkinson's genetics within the Black community.
- Preventable Risks: Research identifies head injuries, pesticide exposure, and nanoplastics as significant environmental risk factors.
- Biological Insights: Scientists have discovered how fasting reduces inflammation and identified new brain pathways linking movement and dopamine.
- Future Research: Stem-cell-derived neurons are providing new models for testing Alzheimer's and Parkinson's treatments.
Emerging therapeutics and early clinical signals
Parkinson’s therapy risvodetinib shows good safety profile in trial: Risvodetinib, developed by Inhibikase Therapeutics for Parkinson's, showed a good safety profile in a Phase 1 trial involving both healthy volunteers and Parkinson’s patients.
Form of vitamin B3 may help manage Parkinson’s disease: A phase 1 clinical trial showed that high-dose vitamin B3 (NR) supplementation increases NAD+ levels in Parkinson's patients, associated with measurable increases in NAD+ levels and observed symptom changes and offering a new avenue for treatment research.
Expanding genetic research and trial-ready cohorts
Four new US sites added to global Parkinson's genetics study: The BLAAC PD study, part of the Global Parkinson's Genetics Program (GP2), aims to understand Parkinson's disease within the Black community by focusing on genetic factors. The addition of four new US sites reflects a broader push to address underrepresentation in genetic research.
This expansion aligns with a wider trend. The Parkinson's Foundation's PD GENEration initiative now offers genetic testing and counseling to people with Parkinson's at no cost, and its PD Trial Navigator pilot program is connecting genetically tested participants directly to relevant clinical trials. Together, these programs are building the infrastructure needed to link genetic characterization with trial-ready patient populations, a model that has direct implications for how sponsors design and recruit for genetically stratified studies.
Environmental risk factors and gene–environment interactions
A substantial number of Parkinson's disease cases can be attributed to preventable risk factors, new research finds: Research from the University of Alabama at Birmingham identified preventable factors, including head injuries and pesticide exposure, as significant contributors to Parkinson's disease.
This finding reinforces a model in which Parkinson's arises from a combination of genetic and environmental factors. For clinical trial design, understanding gene-environment interactions is increasingly important when defining inclusion criteria and identifying patient subpopulations that may respond differently to targeted therapies.
Parkinson’s disease, dementia linked to nanoplastics that may affect the brain: A Duke University study revealed nanoplastics interact with brain proteins, potentially increasing Parkinson’s and dementia risk, underscoring the need for monitoring and reducing environmental plastic pollution.
New biological mechanisms and therapeutic targets
Scientists identify how fasting may protect against inflammation: Cambridge research revealed fasting increases arachidonic acid, reducing inflammation, with implications for conditions like Parkinson's by a mechanism that research links to reduced chronic inflammation in Parkinson's.
Brain pathway linking movement, addiction, and rewards discovered: Researchers identified a previously unknown connection between the cerebellum and basal ganglia that affects dopamine levels and movement control. This finding opens a potential new avenue for Parkinson's therapies that target these specific neural pathways to alleviate motor symptoms.
Advances in disease modeling and regenerative approaches
Stem-cell-derived brain cells hold promise for Alzheimer's, Parkinson's research: University of Wisconsin-Madison researchers successfully grew stem-cell-derived neurons linked to Alzheimer's and Parkinson's, opening new pathways for research and treatment development.
This line of research is now reaching regulatory milestones. The Michael J. Fox Foundation reported that a stem cell therapy for Parkinson's has received limited approval in Japan, marking one of the first regulatory decisions for cell-based interventions in neurodegenerative disease. For sponsors, these developments signal a growing pipeline of genetically and biologically targeted therapies that will require precision enrollment strategies and longitudinal patient engagement.
At Harvard Stem Cell Institute, researchers are using induced pluripotent stem (iPS) cell technology to create patient-derived brain cells that reproduce Parkinson's-related abnormalities in vitro. This approach allows scientists to observe disease mechanisms at the cellular level and screen for compounds that reverse them, using cells derived from patients with specific genetic mutations. For the precision medicine field, this represents a shift toward genetically defined disease models that can inform both drug development and the design of trials targeting specific patient subpopulations.
Research infrastructure and implications for trial design
These individual advances are supported by a broader institutional infrastructure. The NINDS Morris K. Udall Centers of Excellence continue to drive interdisciplinary research on the fundamental causes of Parkinson's, including gene identification, neurobiological mechanisms, and the development and testing of potential therapeutics. For sponsors, this expanding research base means a growing pipeline of genetically defined targets and a patient population that is increasingly characterized at the molecular level.
As Parkinson's research moves increasingly toward genetically defined targets, the operational demands on clinical trials are shifting in parallel. Identifying patients with specific genetic variants, coordinating remote biomarker testing, and maintaining engagement across long development timelines are no longer secondary considerations. They are central to whether precision therapies reach the patients who need them.
Sano works with sponsors and CROs running genetically stratified trials in neurodegenerative disease, providing the infrastructure to connect genetic characterization, patient recruitment, and long-term engagement within a single coordinated system.
To discuss how Sano can support your Parkinson's disease program, get in touch.